MDM2 inhibitor shows efficacy in wild-type p53 cancer models
Jan. 25, 2024
Researchers from the Chinese Academy of Sciences and collaborators reported on the discovery and preclinical characterization of JN-122, a potent spiroindoline derivative that showed a Ki value of 0.7 nM against MDM2.